FibroGen (FGEN) announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock, effective at 5:00 p.m. Eastern Time on June 16. FibroGen’s common stock will begin trading on a split-adjusted basis on June 17, when the markets open, under the company’s existing trading symbol.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FibroGen Amends Financing Agreement for Flexibility
- FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes
- FibroGen’s Strategic Positioning and Financial Health: A Buy Rating Backed by Strong Cash Reserves and Promising Clinical Pipeline
- FibroGen Reports Q1 2025 Earnings and Strategic Updates
- Is FGEN a Buy, Before Earnings?